Diseases that affect the brain or other components of the central nervous system are among the most devastating and complex conditions plaguing mankind today. As populations around the world live longer, diseases related to aging present an unprecedented challenge. Estimates indicate that the number of those who suffer from Alzheimer's around the world will double to 34 million by 2025, while the number of people in the United States alone who have Alzheimer’s disease is expected to nearly triple to 16 million by 2050. Numbers are also rising for those with Parkinson’s disease, which afflicts an estimated 10 million worldwide. Huntington’s disease is less common, but does strike about 1 in 10,000 and is the most frequent inherited neurodegenerative disorder.
At Gladstone, we focus on these diseases and others—such as frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease) and multiple sclerosis—with urgency. And we have discovered much. For example, we have identified processes that can explain why apolipoprotein (apo) E4 is the main genetic risk factor for Alzheimer’s disease and also worsens outcome after traumatic brain injury. These findings have culminated in the computer-aided design of compounds that can block detrimental apoE4 effects. Related studies have elucidated how proteins that build up to abnormally high levels in the brain of Alzheimer patients—amyloid beta, tau and alpha-synuclein—interact to disrupt brain function and promote memory loss. We have turned conventional thinking on its head by revealing that the clumps of proteins, known as inclusion bodies, found in the brain of those with Huntington's disease are actually part of a defense mechanism against the disease—rather than its cause.
We have developed a compound that in animal models protects against signs of Huntington’s and Alzheimer’s. Our scientists have also pointed the way to a new therapeutic strategy for multiple sclerosis and other neurological diseases by identifying that a blood protein, fibrinogen, plays a causal role in damaging the central nervous system. And just recently, a Gladstone scientist developed methods to convert adult skin cells into neurons that are able to transmit electrical signals—expanding capabilities in regenerative and personalized medicine.
But there is still much to do—and no time to lose. We therefore bring together basic scientists, who concentrate on unraveling fundamental mechanisms underlying nervous system functions in health and disease, with physician-scientists who approach their research with a keen eye on unresolved medical problems and patients’ needs. Together, we are dedicated to interdisciplinary research that yields the multi-faceted solutions these complex conditions demand.
We impart this approach to tomorrow’s neuroscientists, whom we train as part of our mission to solve nature’s riddles and overcome disease. Our principal investigators are professors at the University of California, San Francisco (UCSF) and train graduate students and postdoctoral fellows in their labs. Together with major components of UCSF’s Neuroscience Program and Department of Neurology, which are located across the street from Gladstone on UCSF’s Mission Bay campus, we are an integral and collaborative part of one of the nation’s largest collections of neuroscientists and neurologists. To learn more about training at Gladstone, please visit the Training Programs section of our website.